Yüklüyor......
Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
Treprostinil is a potent prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH, World Health Organization Group I). Previously, treprostinil was available only in subcutaneous (SC) or intravenous (IV) formulations. Availability of an inhaled formulation of trep...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Medknow Publications
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3641714/ https://ncbi.nlm.nih.gov/pubmed/23662183 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2045-8932.109926 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|